# Cytosorbents Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Cytosorbents Corp).

## Overview

Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings. Its lead product, CytoSorb, is sold in many countries outside the U.S., while the company is also pursuing regulatory approvals for DrugSorb-ATR and other product candidates in North America.

## Products & services

• CytoSorb blood purification device
• DrugSorb-ATR perioperative antithrombotic removal device
• ECOS-300CY extracorporeal adsorption system
• PuriFi pump device
• VetResQ veterinary blood purification product
• Clinical data, regulatory submissions, and commercialization support

- **CytoSorb therapy** (70%) — Hemoadsorption cartridges used in critical care and cardiothoracic surgery to remove inflammatory mediators and selected substances from blood.
- **DrugSorb-ATR** (10%) — A product candidate designed to remove antithrombotic drugs around surgery to reduce bleeding risk.
- **Other human devices** (10%) — Includes ECOS-300CY, PuriFi and related device offerings used with extracorporeal blood treatment systems.
- **Veterinary products** (5%) — VetResQ products used in animal critical care and veterinary applications.
- **Services and support** (5%) — Regulatory, clinical, and commercialization support tied to product adoption and market expansion.

- CytoSorb blood purification device
- DrugSorb-ATR perioperative antithrombotic removal device
- ECOS-300CY extracorporeal adsorption system
- PuriFi pump device
- VetResQ veterinary blood purification product
- Clinical data, regulatory submissions, and commercialization support

## Customers

The company sells primarily to hospitals, intensive care units, and cardiac surgery teams that use its devices in acute, high-risk procedures. It also targets physicians, healthcare systems, and payers that must be convinced of clinical benefit, reimbursement value, and regulatory acceptance before broad adoption occurs.

- **Critical care hospitals** (primary) — Buy CytoSorb for ICU patients with sepsis, septic shock, respiratory failure, and other acute inflammatory conditions.
- **Cardiothoracic surgery centers** (primary) — Use CytoSorb or DrugSorb-ATR-related therapies to manage bleeding and drug-removal needs around surgery.
- **Physicians and clinical adopters** (primary) — Influence purchasing by adopting the therapy, generating clinical evidence, and driving protocol inclusion.
- **Payers and reimbursement decision-makers** (secondary) — Assess whether the therapy is reimbursed and economically justified, affecting adoption speed.
- **Veterinary customers** (emerging) — Buy VetResQ for animal critical care use, a smaller but strategically relevant niche.

- Hospitals and ICUs buying CytoSorb for critical care use
- Cardiothoracic surgery centers using adsorption in operative settings
- Physicians seeking adjunctive tools for sepsis and shock management
- Healthcare systems and payers evaluating reimbursement and evidence
- Veterinary clinics and animal hospitals for VetResQ applications

## Geography

CytoSorbents is headquartered in Princeton, New Jersey, but its commercial footprint is international, with CytoSorb distributed in more than 70 countries. The company’s core commercial base is outside the U.S., especially in Europe, while U.S. and Canadian growth depends on regulatory approvals that are still pending for key products such as DrugSorb-ATR.

- **Europe** (60%) — Core approved and distributed market for CytoSorb
- **North America** (25%) — Growth depends on FDA and Health Canada approvals
- **Rest of World** (15%) — Distributed in dozens of additional countries

- Headquartered in Princeton, New Jersey, United States
- CytoSorb sold in more than 70 countries worldwide
- European Union is the core approved market for CytoSorb
- U.S. commercialization depends on FDA authorization for key products
- Canada commercialization is tied to Health Canada review of DrugSorb-ATR

## Strategy

Management is focused on expanding commercial adoption while advancing regulatory approvals for DrugSorb-ATR in the U.S. and Canada. At the same time, the company is cutting costs, reducing headcount, and trying to reach cash-flow breakeven to reduce financing pressure and support continued development.

- **U.S. regulatory approval for DrugSorb-ATR** (short-term) — Approval would unlock a large new market and materially improve commercialization prospects.
- **Cost reduction and operating discipline** (short-term) — Lower spending is needed to preserve liquidity and reach cash-flow breakeven.
- **Clinical and market adoption expansion** (medium-term) — Broader physician acceptance and guideline inclusion are needed for sustained sales growth.
- **International commercialization of CytoSorb** (medium-term) — The company already has regulatory access in Europe and many other countries, which remains its main revenue base.

- Advance DrugSorb-ATR through FDA and Health Canada review
- Expand clinical evidence to support adoption and reimbursement
- Grow CytoSorb sales in existing international markets
- Reduce operating costs and move toward cash-flow breakeven
- Secure additional financing to fund commercialization and approvals

## Risks

The company is highly exposed to regulatory outcomes, especially for DrugSorb-ATR in the U.S. and Canada, where approval delays or denials could materially limit growth. It also faces adoption risk because hospitals, physicians, and payers may not accept the therapy without stronger clinical evidence, reimbursement support, and market education. Liquidity and going-concern pressure add financing risk, while competition and Nasdaq listing compliance remain additional business risks.

- **Regulatory failure for DrugSorb-ATR** [high] — The product candidate needs FDA and Health Canada authorization before meaningful North American sales can begin.
- **Market acceptance risk** [high] — Hospitals and clinicians may not adopt the devices without sufficient evidence, reimbursement, and guideline support.
- **Financing and going-concern risk** [high] — Cash resources and operating losses create dependence on external funding and cost reductions.
- **Competitive and reimbursement pressure** [medium] — Competing technologies or unfavorable payer policies could reduce adoption and pricing power.
- **Nasdaq listing compliance** [medium] — Failure to meet listing standards could hurt stock liquidity and investor access to capital.

- FDA or Health Canada rejection could block DrugSorb-ATR commercialization
- Hospital and physician adoption may lag without stronger clinical evidence
- Reimbursement uncertainty can slow uptake and reduce realized demand
- Liquidity pressure may force dilution, spending cuts, or delayed programs
- Nasdaq listing compliance and competition add execution risk

## Accounting

Revenue recognition is important because the company sells medical devices across multiple countries and may also recognize revenue tied to commercialization activities and product launches. Investors should also watch estimates around going-concern disclosures, restructuring charges, stock-based compensation, and any impairment or valuation judgments tied to development-stage assets and financing arrangements.

- **Revenue recognition** — Affects quarterly comparability and growth rates
- **Going-concern assessment** — Signals financing dependence and potential dilution
- **Restructuring charges** — Impacts operating expenses and short-term earnings
- **Stock-based compensation** — Non-cash expense affects profitability trends
- **Royalty expense** — Affects gross margin and operating leverage

- Revenue timing may vary with device shipments, approvals, and channel mix
- Going-concern assessment reflects liquidity and financing uncertainty
- Restructuring charges affect operating expense and near-term comparability
- Stock-based compensation and royalty expense can move SG&A materially
- Development-stage judgments may affect asset valuation and impairment

---

*Last updated: 2026-04-28T20:00:09.678061+00:00*